Gardasil 9

BIOLOGICAL6 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), GlaxoSmithKline, University of Alabama at Birmingham, Rwanda Biomedical Centre, Massachusetts General Hospital

Conditions

CancerCancer HPV InfectionCervical CancerCervical Intraepithelial NeoplasiaHuman Papilloma VirusIdiopathic CD4 T Cell Lymphocytopenia

Phase 1

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

CompletedNCT05496231

GlaxoSmithKlineCervical Intraepithelial Neoplasia

Start: 2022-08-22End: 2024-02-25Updated: 2025-02-03

Phase 2

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Active, not recruitingNCT03519464

National Institute of Allergy and Infectious Diseases (NIAID)Idiopathic CD4 T Cell Lymphocytopenia

Start: 2019-02-04End: 2026-12-31Updated: 2026-08-17

Phase 3

Single dose HPV Immunobridging Study with New Vaccines I (SHINE I)

Active, not recruitingPACTR202407768096289

PATHCancer HPV Infection

Start: 2025-01-03Target: 1320Updated: 2026-09-14

Phase 4

Active, not recruitingPACTR202002647375231

Massachusetts General HospitalCancer

Start: 2018-12-20Target: 2275Updated: 2026-09-14

Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda

Not yet recruitingNCT06536855

Rwanda Biomedical CentreCervical Cancer

Start: 2024-09-01End: 2026-03-30Target: 100000Updated: 2024-08-05

Unknown Phase

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

TerminatedNCT06229353

University of Alabama at BirminghamHuman Papilloma Virus

Start: 2024-08-08End: 2025-07-30Updated: 2026-04-20